Unity Biotechnology, Inc. stock is up 2.6% since 30 days ago. The next earnings date is Mar 13, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 November’s closed higher than October. 100% of analysts rate it a buy.
Unity Biotechnology, Inc. engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye.